A study on molecular characterization of macrolide resistance mechanism among isolates of Streptococcus pneumoniae from the southern Marmara region of Turkey, as well as resistance to macrolides and penicillin in these isolates

被引:2
作者
Ozakin, Cuneyt [2 ]
Guler, Hicran [1 ]
Gurcuoglu, Emel [3 ]
Ozbey, Saliha Bakir [4 ]
Kazak, Esra [2 ]
Sinirtas, Ayse Melda [2 ]
机构
[1] Antalya Med Pk Hosp, Dept Microbiol & Infect Dis, Antalya, Turkey
[2] Uludag Univ, Fac Med, Dept Microbiol & Infect Dis, Bursa, Turkey
[3] Merzifon Hosp, Dept Infect Dis, Amasya, Turkey
[4] Kastamonu Hosp, Dept Infect Dis, Kastamonu, Turkey
关键词
mef(A); erm(B); PCR; S; pneumoniae; ANTIMICROBIAL RESISTANCE; BACTERIAL-RESISTANCE; PYOGENES; SUSCEPTIBILITY; PREVALENCE; PATHOGENS;
D O I
10.3906/sag-1007-975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To determine the distribution of macrolide resistance genes as well as resistance rates in isolated Streptococcus pneumoniae strains from the southern Marmara region of Turkey. Materials and methods: Antimicrobial resistance rates and MIC values were determined by the E-test method in 300 Streptococcus pneumoniae isolates that were isolated from clinical samples. Resistance genes were determined by the polymerase chain reaction (PCR) method in erythromycin-resistant strains. Results: It was found that 11.4% of Streptococcus pneumoniae isolates were resistant to macrolides. The penicillin MIC value was >= 0.12 mu g/mL in 23% of the strains and 2 mu g/mL in 2% of the strains. The erm(B) genotype was observed in 58.8% of all macrolide-resistant strains, 38.2% were of the mef(A) genotype, and 3% were a combination of both genotypes. Conclusion: Based on the data from this study, it was concluded that the local resistance to antibiotics is not as high as that observed in other countries, and the erm(B) genotype was dominant in macrolide-resistant strains. Therefore, it is suggested that macrolide-group antibiotics still be included in treatment protocols.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 23 条
[1]   Antimicrobial susceptibility among communityacquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01 [J].
Doern, GV ;
Brown, SD .
JOURNAL OF INFECTION, 2004, 48 (01) :56-65
[2]   Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study [J].
Farrell, DJ ;
Morrissey, I ;
Bakker, S ;
Felmingham, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :39-47
[3]   Detection of macrolide resistance mechanisms in Streptococcus pneumonide and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization [J].
Farrell, DJ ;
Morrissey, I ;
Bakker, S ;
Felmingham, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :541-544
[4]   Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin [J].
Felmingham, D ;
Reinert, RR ;
Hirakata, Y ;
Rodloff, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :25-37
[5]   International guidelines for the treatment of community-acquired pneumonia in adults - The role of Macrolides [J].
File, TM ;
Tan, JS .
DRUGS, 2003, 63 (02) :181-205
[6]   Treatment of drug-resistant pneumococcal pneumonia [J].
Garau, J .
LANCET INFECTIOUS DISEASES, 2002, 2 (07) :404-415
[7]  
Gulay Z, 2008, JPN J INFECT DIS, V61, P490
[8]   Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes:: results of a multicentre study in Turkey [J].
Gür, D ;
Özalp, M ;
Sümerkan, B ;
Kaygusuz, A ;
Töreci, K ;
Köksal, I ;
Över, U ;
Söyletir, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (03) :207-211
[9]  
Gür D, 2007, MIKROBIYOL BUL, V41, P1
[10]   Meta-analysis of bacterial resistance to macrolides [J].
Halpern, MT ;
Schmier, JK ;
Snyder, LM ;
Asche, C ;
Sarocco, PW ;
Lavin, B ;
Nieman, R ;
Mandell, LA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (05) :748-757